A new era of cardiac nephroprotection in patients with type 2 diabetes mellitus: the role of Finerenone
The main factor in modern healthcare is to increase the length and quality of life of patients, especially with socially significant diseases, such as type 2 diabetes mellitus (T2DM) and its dangerous complication — chronic kidney disease (CKD), associated with a high rate of cardiovascular diseases...
Saved in:
| Main Authors: | I. S. Khalimov, E. A. Polyakova, Yu. A. Shutova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2025-01-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/13222 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Novel cardioprotective and nephroprotective combination in patients with type 2 diabetes and chronic kidney disease: perspectives of use
by: Yu. Sh. Khalimov, et al.
Published: (2024-03-01) -
Finerenone and Estimated GFR Slope in Type 2 Diabetes and CKD
by: Masayuki Yamanouchi, et al.
Published: (2025-07-01) -
Effectiveness of finerenone in Chinese patients with type 2 diabetes mellitus and chronic kidney disease with microalbuminuria: A retrospective real‐world study
by: Yiming Wu, et al.
Published: (2025-06-01) -
Finerenone in diabetic kidney disease: a new frontier for slowing disease progression
by: Ibrahim S. Alhomoud, et al.
Published: (2025-06-01) -
Efficacy and safety of finerenone in non-diabetic CKD patients: a single-center, real-world, retrospective study
by: Yu Li, et al.
Published: (2025-07-01)